Healthcare Industry News: Janssen
News Release - July 17, 2007
Basilea Announces Filing of New Drug Submission in Canada for CeftobiproleBASEL, SWITZERLAND--(Healthcare Sales & Marketing Network)--Jul 17, 2007 -- Basel, Switzerland, July 17, 2007 - Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW ) announced today the filing of a New Drug Submission (NDS) for ceftobiprole with the Therapeutic Products Directorate (TPD) of Health Canada by its license partner Janssen-Ortho, Inc., a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and skin structure infections (cSSSI).
Market applications for the use of ceftobiprole in the treatment of severe skin infections have also been filed in the U.S. by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and in Europe by Janssen-Cilag International NV.
Ceftobiprole is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International.
Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (Swiss:BSLN.SW ). Basilea is currently focused on the development of new antibacterial, antifungal and dermatology drugs.
This communication is intended for information to the financial community only (investors and/or potential investors and their advisors) and expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Source: Basilea Pharmaceutica
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.